Apollo Medical Holdings Inc
NASDAQ:ASTH
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/S
Enterprise Value to Sales (EV/S) ratio compares a company`s total enterprise value to its revenue. It shows how much investors are paying for each dollar of the company`s sales, including both equity and debt.
Enterprise Value to Sales (EV/S) ratio compares a company`s total enterprise value to its revenue. It shows how much investors are paying for each dollar of the company`s sales, including both equity and debt.
Valuation Scenarios
If EV/S returns to its 3-Year Average (0.7), the stock would be worth $36.3 (8% upside from current price).
| Scenario | EV/S Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 0.7 | $33.72 |
0%
|
| 3-Year Average | 0.7 | $36.3 |
+8%
|
| 5-Year Average | 0.7 | $36.3 |
+8%
|
| Industry Average | 2.1 | $100.41 |
+198%
|
| Country Average | 3 | $147.55 |
+338%
|
Forward EV/S
Today’s price vs future revenue
| Today's Enterprise Value | Revenue | Forward EV/S | ||
|---|---|---|---|---|
|
$1.8B
|
/ |
Jan 2026
$3.2B
|
= |
|
|
$1.8B
|
/ |
Dec 2026
$4.1B
|
= |
|
|
$1.8B
|
/ |
Dec 2027
$4.5B
|
= |
|
|
$1.8B
|
/ |
Dec 2028
$4.7B
|
= |
|
|
$1.8B
|
/ |
Dec 2029
$5.1B
|
= |
|
|
$1.8B
|
/ |
Dec 2030
$5.5B
|
= |
|
|
$1.8B
|
/ |
Dec 2031
$6B
|
= |
|
Forward EV/S shows whether today’s EV/S still looks high or low once future revenue are taken into account.
Peer Comparison
| Market Cap | EV/S | P/E | ||||
|---|---|---|---|---|---|---|
| US |
|
Apollo Medical Holdings Inc
NASDAQ:ASTH
|
1.6B USD | 0.7 | 73.3 | |
| US |
|
CVS Health Corp
NYSE:CVS
|
99.1B USD | 0.4 | 56 | |
| US |
C
|
Cigna Group
XMUN:CGN
|
69.7B EUR | 0.4 | 13.5 | |
| US |
|
Cigna Corp
NYSE:CI
|
72.6B USD | 0 | 12.2 | |
| DE |
|
Fresenius Medical Care AG
XMUN:FME
|
23.1B EUR | 1.5 | 23.6 | |
| DE |
|
Fresenius SE & Co KGaA
XETRA:FRE
|
22.7B EUR | 1.4 | 17.9 | |
| US |
|
Quest Diagnostics Inc
NYSE:DGX
|
21.8B USD | 2.4 | 21.4 | |
| US |
|
Laboratory Corporation of America Holdings
NYSE:LH
|
21.7B USD | 1.9 | 24.7 | |
| DE |
F
|
Fresenius Medical Care AG & Co KGaA
XETRA:FME
|
10.8B EUR | 0.9 | 11.1 | |
| US |
|
Guardant Health Inc
NASDAQ:GH
|
11.6B USD | 12.3 | -27.9 | |
| US |
|
DaVita Inc
NYSE:DVA
|
10.4B USD | 1.4 | 13.9 |
Market Distribution
| Min | 0 |
| 30th Percentile | 1.6 |
| Median | 3 |
| 70th Percentile | 5.3 |
| Max | 4 613 320.1 |
Other Multiples
Apollo Medical Holdings Inc
Glance View
Apollo Medical Holdings Inc., often seen as a beacon of innovation within the healthcare industry, operates as a physician-centric, technology-powered company. It is deeply entrenched in the mission of transforming the way healthcare is delivered to populations in the United States. Essentially, ApolloMed’s framework is built around providing integrated care solutions, primarily through coordinating care for over 1.3 million patients via its network of affiliated physicians and medical groups. These medical groups and physicians usually enter into contracts with ApolloMed, which then supports them by offering population health management services, clinical expertise, and innovative technology solutions aimed at improving outcomes and operational efficiencies. The company monetizes its operations through several revenue channels. By contracting with government and private payers, ApolloMed ensures a stable income stream through capitation arrangements and value-based payments, which incentivize quality and cost-effective care for patients. Additionally, its proprietary technology platform plays a pivotal role in enhancing clinical workflows, improving patient engagement, and ensuring better management of medical resources, thereby creating additional efficiencies. This blended model of clinical acumen intersecting with tech innovation, not only aligns the financial interests of providers with that of patients but also allows ApolloMed to bolster its bottom line, while simultaneously adhering to its commitment to high-quality patient care.
